We just need your registered Email Id
to sent your password reset
instructions.
You're doing something extraordinary. We'll keep you in the loop with our latest news and special offers. Please update your profile on a regular basis and be an active community member. Let others know we exist and together we can move medicine forward.
You are now registered within Modern Trials network. If we receive patient inquires within your zip code we will let you know. Be on the look out for an E-Mail from our team.
| NCT Id | NCT04834024 |
|---|---|
| Title | MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma |
| Condition | Follicular Lymphoma and Marginal Zone Lymphoma |
| StudyType | Interventional |
| Organization | Beijing Mabworks Biotech Co., Ltd. |
| Sponsor/Collaborators | Beijing Mabworks Biotech Co., Ltd. |
| Status | Not yet recruiting |
| Gender | All |
| AgeGroup | Adult Older Adult |
| Location (with distance) | |
| Description | This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide. |
Your interest has been recorded and our team is working hard for you. We will contact you with further steps.